- Home
- ZENV vs ECOR Comparison
ZENV vs ECOR Comparison
Compare ZENV & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ECOR
- Stock Information
- Founded
- ZENV 2005
- ECOR 2005
- Country
- ZENV Brazil
- ECOR United States
- Employees
- ZENV N/A
- ECOR N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ZENV Technology
- ECOR Health Care
- Exchange
- ZENV Nasdaq
- ECOR Nasdaq
- Market Cap
- ZENV 63.3M
- ECOR 65.0M
- IPO Year
- ZENV 2021
- ECOR 2018
- Fundamental
- Price
- ZENV $1.36
- ECOR $9.92
- Analyst Decision
- ZENV
- ECOR Strong Buy
- Analyst Count
- ZENV 0
- ECOR 1
- Target Price
- ZENV N/A
- ECOR $15.00
- AVG Volume (30 Days)
- ZENV 80.7K
- ECOR 155.1K
- Earning Date
- ZENV 11-18-2024
- ECOR 11-13-2024
- Dividend Yield
- ZENV N/A
- ECOR N/A
- EPS Growth
- ZENV N/A
- ECOR N/A
- EPS
- ZENV N/A
- ECOR N/A
- Revenue
- ZENV $173,594,726.00
- ECOR $23,327,000.00
- Revenue This Year
- ZENV $21.46
- ECOR $62.51
- Revenue Next Year
- ZENV $9.29
- ECOR $31.32
- P/E Ratio
- ZENV N/A
- ECOR N/A
- Revenue Growth
- ZENV 23.49
- ECOR 74.10
- 52 Week Low
- ZENV $0.88
- ECOR $5.02
- 52 Week High
- ZENV $3.88
- ECOR $14.20
- Technical
- Relative Strength Index (RSI)
- ZENV 54.17
- ECOR 44.64
- Support Level
- ZENV $1.12
- ECOR $9.60
- Resistance Level
- ZENV $1.55
- ECOR $13.93
- Average True Range (ATR)
- ZENV 0.12
- ECOR 1.36
- MACD
- ZENV 0.02
- ECOR -0.51
- Stochastic Oscillator
- ZENV 55.81
- ECOR 7.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.